Bacteria transmit metformin-associated lifespan extension

  title={Bacteria transmit metformin-associated lifespan extension},
  author={Lesley T. MacNeil and Jonathan D. Schertzer and Gregory R. Steinberg},
  journal={Nature Reviews Endocrinology},
Metformin is the mainstay therapy for type 2 diabetes mellitus. A new study shows that metformin acts directly on gut bacteria to elevate cAMP-induced agmatine production, thereby increasing lipid metabolism and lifespan in model organisms. These data identify links between metformin and gut microbiota that might be important for increasing longevity. 

New Insight into Metformin Mechanism of Action and Clinical Application

The evidence linking the effects of metformin on insulin resistance, prediabetes, diabetes, aging, cancer, PCOS, cardiovascular diseases, and neurodegenerative diseases is focused on.

Repurposing drugs to fight aging: The difficult path from bench to bedside

Recent advances and challenges in the field of repurposing widely used conventional pharmaceuticals to target the aging process are summarized and discussed.

Agmatine as a novel candidate for rapid-onset antidepressant response

Evidence is sought about the mechanisms that may underlie the fast antidepressant-like responses of agmatine in preclinical studies and whether it may be investigated as a useful compound for the management of MDD associated with a pro-inflammatory state.

Health and Pro-Longevity Interventions

This chapter discusses whether the conventionally used drugs can be repurposed to target the aging process per se and the advances and challenges in this emerging research field are summarized.

Explaining Health Across the Sciences

This chapter explores what the authors can learn from an evolutionary perspective on health and what may be the implications for future health at a time when human life expectancy has undergone recent, rapid change.



Metformin as Anti-Aging Therapy: Is It for Everyone?

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still

Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1

It is found that metformin increases nematode healthspan, slowing lipofuscin accumulation, extending median lifespan, and prolonging youthful locomotory ability in a dose-dependent manner, suggesting that met formin may be a plausible pharmacological intervention to promote healthy human aging.

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

As met formin modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-α, metformin may be mechanistically well suited for combination with incretIn-based therapies.

Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin

It is established that inhibitory phosphorylation of Acc by Ampk is essential for the control of lipid metabolism and, in the setting of obesity, for metformin-induced improvements in insulin action.

Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients.

It was found that in these participants metformin acts in insulin resistance; it increases glucose muscle uptake and blood flow, and the enhancement of blood flow and lower free fatty acids, not described yet, could be direct effects of the drug or due to reduced glucose toxicity.

Agmatine: clinical applications after 100 years in translation.